Thyroxine-binding globulin as a marker of liver tumors.
This investigation was undertaken to evaluate the level of thyroxine-binding globulin (TBG) as a marker of liver tumors. TBG examination was performed on 42 patients with primary hepatocellular carcinoma (PHC) and 50 postoperative patients with metastases to the liver. alpha-Fetoprotein (AFP) and carcinoembryonic antigen (CEA) concentrations were determined at the same time. AFP was positive in 90.5% of the patients with PHC, and TBG was higher than normal in 69% of patients with PHC. In the 50 patients with liver metastasis, the TBG was higher than normal in 72%, and CEA was also increased in 64%. CEA was negative in 18 of 50 patients with liver metastasis. On the other hand, of the 18 CEA-negative patients, 14 (77.8%) had a higher than normal TBG concentration. This was a significant, but not specific, increase. Therefore, elevated TBG levels are a sensitive, although nonspecific, tumor marker to determine the presence of liver tumors, especially in cases of metastasis to the liver.
D002272:Carcinoembryonic Antigen / Q000032:analysis; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000556:secondary; D008297:Male; D009363:Neoplasm Proteins / Q000032:analysis*; D013975:Thyroxine-Binding Proteins / Q000032:analysis*; D000509:alpha-Fetoproteins / Q000032:analysis
D002272:Carcinoembryonic Antigen; D009363:Neoplasm Proteins; D013975:Thyroxine-Binding Proteins; D000509:alpha-Fetoproteins